Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Yasuyuki, Nakano"'
Autor:
Hiroya Taniguchi, Keisuke Uehara, Goro Nakayama, Hiroshi Nakayama, Toshisada Aiba, Norifumi Hattori, Masato Kataoka, Yasuyuki Nakano, Yoshihisa Kawase, Osamu Okochi, Hiroshi Matsuoka, Setsuo Utsunomiya, Eiji Sakamoto, Yoshinori Mori, Shinichi Umeda, Toshio Shikano, Koji Komori, Masahiro Tajika, Shigenori Kadowaki, Kei Muro, Yasushi Yatabe
Publikováno v:
Translational Oncology, Vol 13, Iss 7, Pp 100786- (2020)
BACKGROUND: Primary tumor location is a critical prognostic factor that also impacts the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in wild-type RAS (KRAS/NRAS) metastatic colorectal cancer (CRC). However, the association betwee
Externí odkaz:
https://doaj.org/article/ef4cda05f303454c8cea476dee81c494
Autor:
Ayumu Matsuoka, Osamu Maeda, Takefumi Mizutani, Yasuyuki Nakano, Nobuyuki Tsunoda, Toyone Kikumori, Hidemi Goto, Yuichi Ando
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168707 (2016)
Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that VEGF recepto
Externí odkaz:
https://doaj.org/article/5497265efae54bf7bb38b88f06c66f43
Autor:
Kei Muro, Yasuyuki Nakano, Shigenori Kadowaki, Goro Nakayama, Shinichi Umeda, Setsuo Utsunomiya, Yoshinori Mori, Toshisada Aiba, Osamu Okochi, Norifumi Hattori, Toshio Shikano, Yoshihisa Kawase, Masato Kataoka, Yasushi Yatabe, Hiroshi Nakayama, Hiroya Taniguchi, Keisuke Uehara, Masahiro Tajika, Hiroshi Matsuoka, Koji Komori, Eiji Sakamoto
Publikováno v:
Translational Oncology
Translational Oncology, Vol 13, Iss 7, Pp 100786-(2020)
Translational Oncology, Vol 13, Iss 7, Pp 100786-(2020)
BACKGROUND: Primary tumor location is a critical prognostic factor that also impacts the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in wild-type RAS (KRAS/NRAS) metastatic colorectal cancer (CRC). However, the association betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0731f847d73adcfb5fadc6de56111cd4
http://europepmc.org/articles/PMC7232108
http://europepmc.org/articles/PMC7232108
Autor:
Yasuyuki Nakano, Chihiro Kondoh, Naoto Sassa, Tomoya Shimokata, Kazunori Honda, Yasushi Yoshino, Bishal Gyawali, Naomi Hayashi, Momokazu Gotoh, Yuichi Ando
Publikováno v:
Molecular and Clinical Oncology. 5:641-646
Some targeted therapies alter muscle mass due to interference with pathways of muscle metabolism. The effects of mammalian target of ra pamycin (mTOR) inhibitors on muscle mass have yet to be fully elucidated. In the present study, the computerized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b338c2c8f41f24074c1ce57c6c2993c8
https://doi.org/10.3892/mco.2016.1015
https://doi.org/10.3892/mco.2016.1015
Autor:
Shoji Arai, Ju-Yong Kim, Yasuyuki Nakano, Toshio Higashino, Akihiro Tamura, Hikaru Miyamoto, Noriko Hasebe
Publikováno v:
Island Arc. 25:111-125
The Hakusan volcano, central Japan, is located in a region where two subducting plates (the Pacific Plate and the Philippine Sea Plate) overlap near the junction of four plates adjacent to the Japanese Islands (the Pacific Plate, the Philippine Sea P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e41dac239f833330ae84af4ce2ad7ed1
https://doi.org/10.1111/iar.12143
https://doi.org/10.1111/iar.12143
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 61:463-467
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d51da9f29260e1eadf83f81da4e4c95f
https://doi.org/10.3925/jjtc.61.463
https://doi.org/10.3925/jjtc.61.463
Autor:
Hidemi Goto, Ayumu Matsuoka, Osamu Maeda, Yasuyuki Nakano, Nobuyuki Tsunoda, Yuichi Ando, Takefumi Mizutani, Toyone Kikumori
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168707 (2016)
PLoS ONE
PLoS ONE
Background Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c48792ccbda9e013a4f32574e89767c0
http://europepmc.org/articles/PMC5167416?pdf=render
http://europepmc.org/articles/PMC5167416?pdf=render
Autor:
Yasuyuki Nakano, Hiroshi Tanaka, Hidemasa Nagai, Shiro Nomura, Hideyuki Kushihara, Mayumi Amano, Nagisa Hamashima
Publikováno v:
Annals of Oncology. 29:vii83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6361a51706e420e71f98e13b4822534
https://doi.org/10.1093/annonc/mdy375.079
https://doi.org/10.1093/annonc/mdy375.079
Autor:
Shuichi Hironaka, Kentaro Yamazaki, Kohei Shitara, Naoki Izawa, Narikazu Boku, Kazuto Nishio, Taito Esaki, Akitaka Makiyama, Yasuyuki Nakano, Tadamichi Denda, Kazuko Sakai, Hiroki Hara, Ichinosuke Hyodo, Hiroyuki Okuda, Yukinori Ozaki, Kei Muro, Wataru Okamoto, Tomohiro Nishina, Yoshiyuki Yamamoto, Takeharu Yamanaka
Publikováno v:
Journal of Clinical Oncology. 36:699-699
699 Background: Plasma levels of VEGF-A short isoforms (VEGF-A110 and -A121) measured by immunological multiparametric chip technique (IMPACT) were reported to be associated with clinical benefits from bevacizumab (BV) in advanced gastric and pancrea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef862a3aacbd56b50cd558c88b8a72a9
https://doi.org/10.1200/jco.2018.36.4_suppl.699
https://doi.org/10.1200/jco.2018.36.4_suppl.699
Autor:
Yoshiyuki Yamamoto, Hisato Kawakami, Yasuyuki Nakano, Kei Muro, Kohei Shitara, Yukinori Ozaki, Shuichi Hironaka, Wataru Okamoto, Akitaka Makiyama, Narikazu Boku, Takashi Ogura, Tadamichi Denda, Ichinosuke Hyodo, Kazuto Nishio, Kazuko Sakai, Hiroki Hara, Masato Komoda, Tomohiro Nishina, Kentaro Yamazaki, Takeharu Yamanaka
Publikováno v:
Journal of Clinical Oncology. 36:670-670
670 Background: Bevacizumab (BV)-containing chemotherapy has been established as the standard first-line treatment for metastatic colorectal cancer (mCRC). However, no biomarkers have been established to predict the clinical benefit of BV for patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d6e24eccf897f9d730a9a147873a9dd
https://doi.org/10.1200/jco.2018.36.4_suppl.670
https://doi.org/10.1200/jco.2018.36.4_suppl.670